Review



massarray system  (agena bioscience)


Bioz Verified Symbol agena bioscience is a verified supplier
Bioz Manufacturer Symbol agena bioscience manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    agena bioscience massarray system
    Massarray System, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 2219 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray-system-1/Methylation/pm30940696-99-1-3
    Average 96 stars, based on 2219 article reviews
    massarray system - by Bioz Stars, 2026-09
    96/100 stars

    Images

    Related Articles

    Sequencing:

    Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025).
    Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, MassARRAY, multiplex PCR, pyrosequencing, and next-generation sequencing. The distribution of PNPLA3 genotypes and other study characteristics are presented in Table 1 and Supplementary Table S2 (Supp

    Real-time Polymerase Chain Reaction:

    Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025).
    Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, MassARRAY, multiplex PCR, pyrosequencing, and next-generation sequencing. The distribution of PNPLA3 genotypes and other study characteristics are presented in Table 1 and Supplementary Table S2 (Supp

    Polymerase Chain Reaction:

    Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025).
    Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, MassARRAY, multiplex PCR, pyrosequencing, and next-generation sequencing. The distribution of PNPLA3 genotypes and other study characteristics are presented in Table 1 and Supplementary Table S2 (Supp

    Multiplex PCR:

    Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025).
    Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, MassARRAY, multiplex PCR, pyrosequencing, and next-generation sequencing. The distribution of PNPLA3 genotypes and other study characteristics are presented in Table 1 and Supplementary Table S2 (Supp

    Multiplex Assay:

    Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025).
    Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, MassARRAY, multiplex PCR, pyrosequencing, and next-generation sequencing. The distribution of PNPLA3 genotypes and other study characteristics are presented in Table 1 and Supplementary Table S2 (Supp

    Next-Generation Sequencing:

    Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025).
    Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, MassARRAY, multiplex PCR, pyrosequencing, and next-generation sequencing. The distribution of PNPLA3 genotypes and other study characteristics are presented in Table 1 and Supplementary Table S2 (Supp

    Concentration Assay:

    Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025).
    Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, MassARRAY, multiplex PCR, pyrosequencing, and next-generation sequencing. The distribution of PNPLA3 genotypes and other study characteristics are presented in Table 1 and Supplementary Table S2 (Supp

    Mass Spectrometry:

    Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025).
    Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, MassARRAY, multiplex PCR, pyrosequencing, and next-generation sequencing. The distribution of PNPLA3 genotypes and other study characteristics are presented in Table 1 and Supplementary Table S2 (Supp

    Amplification:

    Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025).
    Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, MassARRAY, multiplex PCR, pyrosequencing, and next-generation sequencing. The distribution of PNPLA3 genotypes and other study characteristics are presented in Table 1 and Supplementary Table S2 (Supp

    Protein-Protein interactions:

    Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025).
    Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, MassARRAY, multiplex PCR, pyrosequencing, and next-generation sequencing. The distribution of PNPLA3 genotypes and other study characteristics are presented in Table 1 and Supplementary Table S2 (Supp

    Functional Assay:

    Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025).
    Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, MassARRAY, multiplex PCR, pyrosequencing, and next-generation sequencing. The distribution of PNPLA3 genotypes and other study characteristics are presented in Table 1 and Supplementary Table S2 (Supp



    Similar Products

    96
    agena bioscience massarray system
    Massarray System, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray-system-1/Methylation/pm30940696-99-1-3
    Average 96 stars, based on 1 article reviews
    massarray system - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    agena bioscience massarray system methylation detection amplification pcr reaction
    Massarray System Methylation Detection Amplification Pcr Reaction, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray-system-1/Methylation/pm31002356-111-8-15
    Average 96 stars, based on 1 article reviews
    massarray system methylation detection amplification pcr reaction - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    agena bioscience agena massarray system methylation detection amplification pcr reaction
    Agena Massarray System Methylation Detection Amplification Pcr Reaction, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray-system-1/Methylation/pm31002356-111-7-15
    Average 96 stars, based on 1 article reviews
    agena massarray system methylation detection amplification pcr reaction - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    90
    Sequenom oncocarta v.1 massarray system
    Oncocarta V.1 Massarray System, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray-system-1/massarray+oncocarta+mutation+profiler+panel/pm20815376-108-8-12
    Average 90 stars, based on 1 article reviews
    oncocarta v.1 massarray system - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results